Skip to main content
SCLX
NASDAQ Life Sciences

Scilex Unwinds Vivasor Stake in $12M Related-Party Sale

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$7.03
Mkt Cap
$59.694M
52W Low
$2.615
52W High
$21.338
52W Position info
169% above low
Off High info
67% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

SCLX has more than doubled off its 52-week low of $2.615.

Summary

Scilex Holding Co. agreed to sell its Vivasor preferred shares back to Vivasor for $12 million in a related-party deal, providing cash but raising governance concerns.


Key Events · M&A and Partnerships · SCLX

  • Vivasor Stake Sold Back

    Scilex sold 6,101,468 Series A-1 and 355,919 Series A-2 preferred shares of Vivasor back to Vivasor for $11,999,762.28, unwinding an investment made in January 2026.

  • Related-Party Transaction

    Because Scilex CEO Henry Ji is also CEO of Vivasor, this qualifies as a related-party deal. The agreement includes broad releases of claims by Scilex against Vivasor.

  • Payment Structure

    Vivasor pays in five tranches: $1M at signing, $5M by Sept 30, 2026, and three $2M payments through June 30, 2027. Vivasor can pay in cash or Datavault AI stock.

  • Liquidity Impact

    The $12M provides cash to Scilex, which has a going-concern warning and negative operating cash flow, but the deferred payments mean only $1M is received upfront.


Analysis · SCLX · Life Sciences

Scilex is selling its entire stake in Vivasor Holding Company—6.1 million Series A-1 and 355,919 Series A-2 preferred shares—back to Vivasor for $12 million. The deal unwinds an investment made just six months ago and carries a related-party tag because Scilex CEO Henry Ji also leads Vivasor. Payment is spread over five tranches through mid-2027, and Vivasor can settle in cash or by handing over Datavault AI stock. For a company with a going-concern warning and negative cash flow, the $12 million provides near-term liquidity, but the structure and related-party nature raise governance questions.

At the time of this filing, SCLX was trading at $7.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.7M. The 52-week trading range was $2.62 to $21.34. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SCLX - Latest Insights

SCLX
Jul 07, 2026, 9:26 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $9.50
Real-time Price: $7.03 info
Change: -$2.47 (-26%) info
Market Cap: $59.694M info
SCLX
Jul 06, 2026, 6:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $9.08
Real-time Price: $7.03 info
Change: -$2.05 (-23%) info
Market Cap: $59.694M info
SCLX
Jun 29, 2026, 5:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.80
Real-time Price: $7.03 info
Change: -$0.770 (-10%) info
Market Cap: $59.694M info
SCLX
Jun 24, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.86
Real-time Price: $7.03 info
Change: +$0.170 (+2%) info
Market Cap: $59.694M info
SCLX
Jun 02, 2026, 5:09 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $7.40
Real-time Price: $7.03 info
Change: -$0.370 (-5%) info
Market Cap: $59.694M info